Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent

Journal of Psychiatric Practice
Sheldon H PreskornGLYX-13 Clinical Study Group

Abstract

Approximately 45% of patients with major depressive disorder (MDD) do not remit when treated with biogenic amine antidepressants. Consequently, there is a significant need for antidepressant agents with different mechanisms of action. Early proof of concept (POC) studies with such novel agents play a significant role in helping drug developers identify agents and mechanisms of action that merit more intensive research. Studies have demonstrated that high affinity N-methyl-Daspartate (NMDA) receptor blockers (eg, ketamine) can produce rapid antidepressant effects in patients who have not responded to currently available agents, but treatment with these agents is accompanied by psychotomimetic effects that make their use problematic. This column describes a POC study involving GLYX-13, an N-methyl-D-aspartate receptor glycine site functional partial agonist. In this double-blind, randomized, placebo-controlled study, a single intravenous (IV) dose of GLYX-13 (1, 5, 10, or 30 mg/kg) or placebo was administered to 116 subjects with MDD who had not benefitted from a trial of at least one biogenic amine antidepressant during the current episode. The primary outcome measure was score on the Hamilton Depression Rating Scale-17 (Ham-D17...Continue Reading

References

Feb 25, 2000·Biological Psychiatry·R M BermanJ H Krystal
Mar 21, 2003·Nature·Yi NongMichael W Salter
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Jan 5, 2006·The American Journal of Psychiatry·Carlos A ZarateDennis S Charney
May 9, 2006·Journal of Affective Disorders·Uriel Heresco-LevyIlana Kremer
Aug 9, 2006·Archives of General Psychiatry·Carlos A ZarateHusseini K Manji
Jan 29, 2008·Current Psychiatry Reports·Diane WardenStephen R Wisniewski
Sep 23, 2009·CNS Neuroscience & Therapeutics·Gregory M ChandlerMaurizio Fava
Oct 20, 2009·Trends in Pharmacological Sciences·Phil SkolnickRamon Trullas
Nov 10, 2009·Biological Psychiatry·Marije aan het RotSanjay J Mathew
Feb 19, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Shashank M DravidStephen F Traynelis
Nov 24, 2012·The International Journal of Neuropsychopharmacology·Uriel Heresco-LevyIlana Kremer
Jan 11, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffrey BurgdorfJoseph R Moskal

❮ Previous
Next ❯

Citations

Feb 9, 2016·Drug Discovery Today·Danielle M GerhardRonald S Duman
Sep 24, 2015·Pharmaceuticals·Shigeyuki Chaki, Kenichi Fukumoto
Oct 4, 2015·Neuroscience and Biobehavioral Reviews·David S BredtHusseini K Manji
Jan 20, 2016·Current Behavioral Neuroscience Reports·Sara CostiJames W Murrough
Jan 12, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Matthew D CooperRoger S McIntyre
Mar 13, 2015·Annals of the New York Academy of Sciences·Alan F Schatzberg
Oct 6, 2016·BJPsych Open·Gin S MalhiMauricio Tohen
Mar 12, 2002·Journal of Psychiatric Research·Richard Entsuah, Jack M Gorman
Jul 14, 2016·Expert Opinion on Drug Discovery·Agnieszka Pałucha-Poniewiera, Andrzej Pilc
Sep 13, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·João Data-FrancoOlivia M Dean
Dec 15, 2016·Expert Opinion on Investigational Drugs·Ashish Dhir
Jan 17, 2017·Expert Review of Neurotherapeutics·Ricardo P GarayPierre-Michel Llorca
Jun 10, 2017·Expert Review of Neurotherapeutics·Gopalkumar RakeshPrakash S Masand
Aug 4, 2016·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Sidney H KennedyUNKNOWN CANMAT Depression Work Group
Oct 27, 2016·Expert Review of Clinical Pharmacology·Ioline D HenterRodrigo Machado-Vieira
Mar 17, 2018·Nature Reviews. Neuroscience·Marc P ForrestPeter Penzes
Mar 9, 2018·CNS Drugs·Panos ZanosTodd D Gould
Nov 2, 2017·Psychopharmacology·Satoshi DeyamaMasabumi Minami
Nov 22, 2017·Molecular Psychiatry·C JiangS R Salton
Jun 20, 2018·The Journal of Physiology·Alasdair J GibbStephen F Traynelis
Feb 22, 2018·Harvard Review of Psychiatry·Ioline D HenterCarlos A Zarate
Feb 2, 2018·Acta Neuropsychiatrica·Vitor Silva Pereira, Vinícius Antonio Hiroaki-Sato
Dec 27, 2018·Expert Opinion on Investigational Drugs·Renee-Marie RagguettRoger S McIntyre
Oct 10, 2018·Annual Review of Pharmacology and Toxicology·Todd D GouldScott M Thompson
Dec 14, 2018·The International Journal of Neuropsychopharmacology·John E DonelloJoseph R Moskal
Nov 18, 2018·The International Journal of Neuropsychopharmacology·Bashkim KadriuCarlos A Zarate
Dec 15, 2015·Journal of Clinical Psychopharmacology·Yena LeeRoger S McIntyre
Oct 2, 2019·Current Neuropharmacology·Kaipuzha Venu AthiraSumana Chakravarty
Sep 27, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gerard Sanacora, Alan F Schatzberg
Aug 31, 2016·Current Behavioral Neuroscience Reports·Dawn F Ionescu, George I Papakostas
Mar 23, 2017·Translational Psychiatry·D F Ionescu, G I Papakostas
Feb 2, 2019·Frontiers in Neuroscience·Kenneth L Davis, Christian Montag

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.